Chloroquine for COVID-19: Cutting Through the Hype
President Donald Trump has touted the drug as a treatment but scientists still don’t know for sure that it is effective in patients. A number of clinical trials aim to find out.
Chloroquine for COVID-19: Cutting Through the Hype
Chloroquine for COVID-19: Cutting Through the Hype
President Donald Trump has touted the drug as a treatment but scientists still don’t know for sure that it is effective in patients. A number of clinical trials aim to find out.
President Donald Trump has touted the drug as a treatment but scientists still don’t know for sure that it is effective in patients. A number of clinical trials aim to find out.
With mounting feelings of isolation, research projects derailed, and financial futures cast into doubt, grad students are anxious in the midst of the COVID-19 outbreak.
Rhesus macaques can be infected with SARS-CoV-2, leading primate center scientists to try to prevent outbreaks in their colonies, especially as experiments on coronavirus start.
Amy Schleunes and Catherine Offord | Mar 19, 2020 | 1 min read
International data from the European Centre for Disease Prevention and Control indicates a similar pattern in reported coronavirus cases during the first 10 days after the case count passes 500.
Disease experts have largely focused on how we got to where we are now with coronavirus infections. Improved data collection and sharing can enhance projections of what’s to come.
A preprint indicates that coronavirus transmission from surfaces is possible, but does not provide evidence that this has occurred in the COVID-19 pandemic.
It takes a median of five days after infection to get sick, and patients shed the most coronavirus particles early in the illness, according to two new reports.
China and Japan have also closed their schools, prompting universities worldwide to assess the threat this virus poses to their local and international communities.
Administration officials have given contradictory statements about how COVID-19 will affect the US, and it is not clear who is leading the infectious disease response effort, critics say.
Researchers look to messenger RNA encased in nanoparticles, DNA plasmids, molecular clamps, and other approaches as they rush to design a vaccine against the new coronavirus.
Saliva tests screen staff and students at University of Illinois; Study ranks species most susceptible to SARS-CoV-2 infection; COVID-19 clinical trials test drugs that inhibit kinin system